Camurus (Octreotide FluidCrystal Product CAM2029) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 2

Camurus (Octreotide FluidCrystal Product CAM2029) General Information

Description

Global rights of acromegaly and neuroendocrine tumors drug.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 224 84 Lund
  • Sweden
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Corporate Office
  • 224 84 Lund
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Camurus (Octreotide FluidCrystal Product CAM2029) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Camurus (Octreotide FluidCrystal Product CAM2029)‘s full profile, request access.

Request a free trial

Camurus (Octreotide FluidCrystal Product CAM2029) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Camurus (Octreotide FluidCrystal Product CAM2029)‘s full profile, request access.

Request a free trial

Camurus (Octreotide FluidCrystal Product CAM2029) FAQs

  • Where is Camurus (Octreotide FluidCrystal Product CAM2029) headquartered?

    Camurus (Octreotide FluidCrystal Product CAM2029) is headquartered in Lund, Sweden.

  • What industry is Camurus (Octreotide FluidCrystal Product CAM2029) in?

    Camurus (Octreotide FluidCrystal Product CAM2029)’s primary industry is Buildings and Property.

  • Is Camurus (Octreotide FluidCrystal Product CAM2029) a private or public company?

    Camurus (Octreotide FluidCrystal Product CAM2029) is a Private company.

  • What is Camurus (Octreotide FluidCrystal Product CAM2029)’s current revenue?

    The current revenue for Camurus (Octreotide FluidCrystal Product CAM2029) is .

  • Who are Camurus (Octreotide FluidCrystal Product CAM2029)’s investors?

    Camurus and Novartis have invested in Camurus (Octreotide FluidCrystal Product CAM2029).

  • When was Camurus (Octreotide FluidCrystal Product CAM2029) acquired?

    Camurus (Octreotide FluidCrystal Product CAM2029) was acquired on 03-May-2018.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process